Publicacións nas que colabora con Francisco Orallo Cambeiro (34)

2013

  1. Cyclic AMP relaxation of rat aortic smooth muscle is mediated in part by decrease of depletion of intracellular Ca2+ stores and inhibition of capacitative calcium entry

    Vascular Pharmacology, Vol. 58, Núm. 1-2, pp. 98-104

2011

  1. Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors

    Journal of Medicinal Chemistry, Vol. 54, Núm. 14, pp. 5165-5173

  2. New butyrolactone from a marine-derived fungus aspergillus SP

    Journal of the Chilean Chemical Society, Vol. 56, Núm. 1, pp. 625-627

  3. Trans-resveratrol simultaneously increases cytoplasmic Ca 2+ levels and nitric oxide release in human endothelial cells

    Molecular Nutrition and Food Research, Vol. 55, Núm. 8, pp. 1237-1248

2010

  1. Antidepressant-like profile and MAO-A inhibitory activity of 4-propyl-2H-benzo[h]-chromen-2-one

    Life Sciences, Vol. 86, Núm. 21-22, pp. 819-824

  2. New pyridazinone derivatives with vasorelaxant and platelet antiaggregatory activities

    Bioorganic and Medicinal Chemistry Letters, Vol. 20, Núm. 22, pp. 6624-6627

  3. Synthesis and vasorelaxant and platelet antiaggregatory activities of a new series of 6-Halo-3-phenylcoumarins

    Molecules, Vol. 15, Núm. 1, pp. 270-279

2009

  1. A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors

    Bioorganic and Medicinal Chemistry Letters, Vol. 19, Núm. 12, pp. 3268-3270

  2. Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors

    Molecular Pharmaceutics, Vol. 6, Núm. 3, pp. 825-835

  3. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors

    Bioorganic and Medicinal Chemistry Letters, Vol. 19, Núm. 17, pp. 5053-5055

2008

  1. Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors

    Journal of Medicinal Chemistry, Vol. 51, Núm. 21, pp. 6740-6751

  2. Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca 2+ responses in endothelial cells

    British Journal of Pharmacology, Vol. 154, Núm. 1, pp. 82-92

2007

  1. Effects of (-)-epigallocatechin-3-gallate in Ca2+-permeable non-selective cation channels and voltage-operated Ca2+ channels in vascular smooth muscle cells

    Life Sciences, Vol. 80, Núm. 23, pp. 2147-2153

  2. Effects of trans- and cis-resveratrol on Ca2+ handling in A7r5 vascular myocytes

    European Journal of Pharmacology, Vol. 577, Núm. 1-3, pp. 91-99

2006

  1. Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta

    British Journal of Pharmacology, Vol. 147, Núm. 3, pp. 269-280

2005

  1. Trans- and cis-resveratrol increase cytoplasmic calcium levels in A7r5 vascular smooth muscle cells

    Molecular Nutrition and Food Research, Vol. 49, Núm. 5, pp. 396-404

2004

  1. (-)-Epigallocatechin-3-gallate induces contraction of the rat aorta by a calcium influx-dependent mechanism

    Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 369, Núm. 5, pp. 496-506

  2. Effects of cis-resveratrol on inflammatory murine macrophages: Antioxidant activity and down-regulation of inflammatory genes

    Journal of Leukocyte Biology, Vol. 75, Núm. 6, pp. 1156-1165

2002

  1. Synthesis and vasorelaxant activity of new coumarin and furocoumarin derivatives

    Bioorganic and Medicinal Chemistry Letters, Vol. 12, Núm. 5, pp. 783-786

2000

  1. Cardiovascular effects of ketanserin on normotensive rats in vivo and in vitro

    General Pharmacology: The Vascular System, Vol. 35, Núm. 2, pp. 95-105